Endo International plc announced that its operating company Endo Pharmaceuticals Inc. received FDA approval on 5 March 2014 of Aveed...
Endo International plc announced the publication of data from a population pharmacokinetic (PK) modeling and simulation study, evaluating potential dosing flexibility of Aveed (testosterone undecanoate) in hypogonadal males.
Endo Pharmaceuticals has received a third Complete Response Letter (CRL) from the FDA, asking for tighter safety measures before it...
Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer’s men’s health product Nebido (testosterone undecanoate), for a purchase price totaling up to 500 million Euro.